S	ubstitute for form 1449APTO			COMPLETE IF KNOWN			
	NFORMATION	DIS	CLOSURE	Application Number	10/538,395		
6	TATEMENT D	67 A TO	DI ICANIT	Filing Date	June 9, 2005		
3	TATEMENT BY	Y AP	PLICANI	First Named Inventor	Linus S. Lin et al.		
				Group Art Unit			
	(use as many shee	is as n	ecessary)	Examiner Name			
Sheet	1	of	4	Attorney Docket Number	21261P		

			U.S. PA	TENT DOCUMENTS		
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
MVI		6344474		MARUANI et al.	02/05/2002	
		2005/0154202		FONG et al.	08/04/2005	
		2005/0182103		FINKE et al.	08/18/2005	
		2004/0248956		HAGMANN et al.	12/09/2004	
		2003/0114495		FINKE et al.	06/19/2003	
		2004/0058820		HAGMANN et al.	03/25/2004	
		2004/0224962		COE et al.	11/11/2004	
		6359175		PHILIPPE et al.	03/19/2002	
		2004/0224963		COE et al.	11/11/2004	
		2005/0171161		FONG et al.	08/04/2005	
V		2005/0137159		BAB et al.	06/23/2005	
			-			
			-		·	
			_			
			+			

				FORE	GN PATENT	F DOCUMENTS	
		<u> </u>		Foreign Patent Document	nt		Date of Publication of
lni	Examiner Cit Initials* No		Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
_/	YV/	<u> </u>		WO 98/33765 -		E.I. DuPont De Nemours and Company	08/06/1998
				WO 98/56754 -		L'Oreal	12/17/1998
				WO 2004/012671 ·		Merck & Co., Inc.	02/12/2004
				WO 2005/020988 1		Solvay Pharmceuticals GMBH	03/10/2005
			Ţ	WO 2005/020992 ·		Solvay Pharmceuticals GMBH .	03/10/2005
			İ	WO 2005/027837 ·		Merck & Co., Inc.	03/31/2005
			ľ	WO 2005/043327 .		Docomo Communications Laboratories USA, Inc.	05/12/2005
			ľ	WO 2004/048317-		Merck & Co., Inc.	06/10/2004
S	1			WO 2005/000301 ·		F. Hoffmann-La Roche AG	01/06/2005
	V		1	WO 2005/000809		Merck & Co., Inc.	01/06/2005

Examiner Signature Date Considered 03/20/2007 /Yevgeny Valenrod/

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form 1DS Form (IDS Folder), Merck & Co., Inc., -7/12/2005

				PARENT AND THROSTER CHIESE, U.S DEPARTMENT OF COMMERCE
Substitute for form 1449A/PTC	<u> </u>		(COMPLETE IF KNOWN
INFORMATIO	N DIS	CLOSURE	Application Number	10/538,395
CTATEMENT :	DV AD	DI ICANT	Filing Date	June 9, 2005
STATEMENT	DI AF	FLICANI	First Named Inventor	Linus s. Lin et al.
			Group Art Unit	
(use as many sh	eeis as n	ecessary)	Examiner Name	·
2	of	4	Attorney Docket Number	21261P
	INFORMATIO STATEMENT	STATEMENT BY AP	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Application Number Filing Date First Named Inventor Group Art Unit Examiner Name

	U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code (known)		Date of Publication of Cited Document MM-DD-YYYY					
			-							
				·						

		FORE	IGN PATENT	DOCUMENTS	
Examiner Initials*	Cite No.	Foreign Patent Docume Office Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
/YV/		WO 2005/009479		Merck & Co., Inc.	02/03/2005
		WO 03/009005		Westerngeco Seismic Holdings Limited	01/30/2005
		WO 03/007887		Merck & Co., Inc.	01/30/2003
		WO 01/58450		Sanofi-Synthelabo	08/16/2001
		WO 01/09120		Ortho-McNeil Pharmaceutical, Inc.	02/08/2001
		WO 03/063781		Merck & Co., Inc.	08/07/2003
		WO 03/075660		Merck & Co., Inc.	09/18/2003
		WO 03/077847		Merck & Co., Inc.	09/25/2003
		WO 2003/082256		Sanofi-Synthelabo	10/09/2003
V		WO 03/087037		Merck & Co., Inc.	10/23/2003

Examiner Signature /Yevgeny Valenrod/ Date Considered 03/20/2007

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder). Merck & Co., Inc., -7/12/2005)

S	distitute for form 1449A/PTO				COMPLETE IF KNOWN	
	NFORMATION	DIS	CLOSURE	Application Number	10/538,395	
	OF A OPEN ATONION TO	17 A TO	DIICANT	Filing Date	June 9, 2005	
3	TATEMENT BY	Y AP	PLICANI	First Named Inventor	Linus S. Lin et al.	
				Group Art Unit		*
	(use as many shee	ts as n	ecessary)	Examiner Name		
Sheet	3	of	4	Attorney Docket Number	21261P	

	U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code		Date of Publication of Cited Document MM-DD-YYYY					
					F0					
		·								
•										

	FOREIGN PATENT DOCUMENTS										
			Foreign Patent Document	:	·	Date of Publication of					
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY					
7YV/			WO 2005/039550 ~		Solvay Pharmaceuticals GMBH	05/06/2005					
/YV/			WO 03/082833 ·		Consejo Superior De Investigaciones Científicas & Universidad Rey Juan Carlos	10/09/2003					
/YV/			WO 03/086288.		Merck & Co., Inc.	10/23/2003					
/YV/			WO 04/029204		Merck & Co., Inc.	04/08/2004					
											

Examiner Signature / Yevgeny Valenrod/ Date Considered 03/20/2007

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/03A (07-05), Information Disclosure Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

	bstitute for form 1449B/PTO	•			COMPLETE IF KNOWN
	NFORMATION 1	DIS	CLOSURE	Application Number	10/538,395
	TATEMENT BY	A ID	DI ICANIT	Filing Date	June 9, 2005
3	IAIEMENI DI	AF	PLICANI	First Named Inventor	Linus S. Lin et al.
				Group Art Unit	
	(use as many sheets	as n	ecessary)	Examiner Name	
Sheet	4	of	4	Attorney Docket Number	21261P

			NON PATENT LITERATURE DOCUMENTS
Exami Initial		Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
ΛΛΛΙ		AA	Lange et al., Drug Discovery Today, Vol. 10 (2005), pp. 693-702, "Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists",
	AB Petitet et al., Emerging Drugs, Vol. 3 (1998), pp. 39-53, "The therapeutic appliagonists and antagonists"		Petitet et al., Emerging Drugs, Vol. 3 (1998), pp. 39-53, "The therapeutic applications of cannabinoid agonists and antagonists"
		AC	Di Marzo et al., Emerging Therapeutic Targets, Vol. 5 (2001), pp. 241-265, "Endocannabinoids Part I: Molecular basis fo endocannabinoid formation, action and inactivation and development of selectie inhibitors"
		AD	Goya et al., Exp. Opin. Ther. Patents, Vol. 10 (2000), pp. 1529-1538, "Recent advances in cannabinoid receptor agonists and antagonists"
		AE	Adam et al., Exp. Opin. Ther. Patents, Vol. 12 2002), pp. 1475-1489, "Recent advances in the cannabinoids"
		AF	Barth, Exp. Opin. Ther. Patents, Vol. 8 (1998), pp. 301-313, "Cannabinoid receptor agonists and antagonists"
		AG	Ito et al., Chem. Pharm. Bull., Vol. 20 (1972), pp. 1762-1767, "Catalytic hydrogenation of tetrahydro-4H-1,3-oxazin-4-ones and 4-oxazolidinones"
		AH	Ishiwata et al., Yakugaku Zashi, Vol. 71 (1951), pp. 1272-1274, "Studies on the syntheses of isoquinoline derivatives"
		AI	Grundy et al., Exp. Opin. Investig. Drugs, Vol. 11 (2002), pp. 1365-1374, "The therapeutic potential of the cannabinoids in neuroprotection"
		AJ	Pines et al., J. Med. Chem., Vol. 10 (1967), pp. 725-728, "The stereochemistry of 2,3-diphenyl-1-methylpropylamine"
		AK	Schultz et al., J. Med. Chem., Vol. 10 (1967), pp. 717-724, "Maleamic acids that affect plasma cholesterol and penicillin excretion"
\downarrow	/	AL	Le Foll et al., J. Pharmacol. Exp. Ther., Vol. 312 (2005), pp. 875-883, "Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence"
		•	

Examiner Signature	/Yevgeny Valenrod/	Date Considered	03/20/2007

Substitute for form 1449A/PTO INFORMATION DI OSURE			COMPLETE IF KNOWN			
			Application Number	10/5		
STATEMENT BY APPLICANT (use as many sheets as necessary)			Filing Date	June 9, 2005		
			First Named Inventor	Linus S. Lin et al.		
			Group Art Unit			
			Examiner Name			
t 1	of	2	Attorney Docket Number	21261P		
	INFORMATION STATEMENT B	INFORMATION DI STATEMENT BY AP (use as many sheets as no	INFORMATION DI COSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	INFORMATION DI LOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Filing Date First Named Inventor Group Art Unit Examiner Name	INFORMATION DI OSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Application Number 10/5 Filing Date June 9, 2005 First Named Inventor Linus S. Lin et al. Group Art Unit Examiner Name	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Docum	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
						
			-			
				····		
		· · · · · · · · · · · · · · · · · · ·				
						
						
		······································				
						
	<u> </u>					
1						

			FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite		Foreign Patent Document				Date of Publication of
	No.	Office Number		Kind Code (if known)	Name of Patentee or Applicant of Cited Document		Cited Document MM-DD-YYYY
/YV/			GB 899,556		Farbwerke Hoechst Aktie	engesellschaft	06/27/1962
/YV/			GB 1,172,346		Parke, Davis & Company	/	11/26/1969
		 					
		├	· · · · · · · · · · · · · · · · · · ·				
							ļ <u>-</u>
-			<u> </u>				
		\vdash					
Examine	er		Novgony Volonzadi		Date		
Signature			/Yevgeny Valenrod/	T .	Conside	_{red} 03/2	20/2007

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

				PERMITE TRACERED CONTRACTOR OF COSCHERCE		
hstitute for form 1449B/PTO			COMPLETE IF KNOWN			
INFORMATION DISCOSURE STATEMENT BY APPLICANT			Application Number	10/5		
			Filing Date	June 9, 2005		
			First Named Inventor	Linus S. Lin et al.		
			Group Art Unit			
(use as many sneets as necessary)			Examiner Name			
2	of	2	Attorney Docket Number	21261P		
	TATEMENT B	NFORMATION DIL TATEMENT BY AP (use as many sheets as n	TATEMENT BY APPLICANT . (use as many sheets as necessary)	Application Number Filing Date First Named Inventor (use as many sheets as necessary) Figure 1		

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.						
		·						
		·						
		·						
		, and the state of						

Examiner	/Yevgeny Valenrod/	Date	
Signature	rrevgerry valerriou/	Considered	03/20/2007
		Considered	10,20,200,

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.